UPDATE: H.C. Wainwright Starts F-Star Therapeutics Inc. (FSTX) at Buy

H.C. Wainwright analyst Pat Trucchio initiates coverage on F-Star Therapeutics Inc. (NASDAQ: FSTX) with a Buy rating and a price target of $35.00.

The analyst commented, "F-star, based in Cambridge, U.K., and Cambridge, Massachusetts, is a clinical stage immuno-oncology (I-O) company focused on developing next generation tetravalent mAb² bispecific antibodies (bsAb). Led by a veteran team that collectively has brought 20 drugs to market, F-star currently has three bsAbs in or nearing clinical trials for various cancer indications; the most advanced candidate, FS118, is expected to generate Phase 2 data in 1Q22. Overall, we find F-star's valuation to be very compelling ahead of potentially positive data updates across the platform over the next 12 months. Hence, we initiate with a Buy rating and $35 price target."

For an analyst ratings summary and ratings history on F-Star Therapeutics Inc. click here. For more ratings news on F-Star Therapeutics Inc. click here.

Shares of F-Star Therapeutics Inc. closed at $8.27 yesterday.

You May Also Be Interested In

• UPDATE: CIBC Starts Gatos Silver (GATO) at Outperformer
• UPDATE: Wedbush Assumes Twitter, Inc. (TWTR) at Neutral
• Aegis Capital Starts Gladstone Commercial (GOOD) at Buy